American Association for Cancer Research
15357163mct140794t-sup-137962_1_supp_2758376_nfkpk7.docx (889.3 kB)

Supplementary Figures S1-S5 from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines

Download (889.3 kB)
journal contribution
posted on 2023-04-03, 14:44 authored by Fei Huang, Han Chang, Ann Greer, Stephen Hillerman, Karen A. Reeves, Warren Hurlburt, John Cogswell, Dharmesh Patel, Zhenhao Qi, Craig Fairchild, Rolf-Peter Ryseck, Tai W. Wong, Friedrich G. Finckenstein, Jeffrey Jackson, Joan M. Carboni

Supplementary Figures S1-S5. Supplementary Figure S1. Similarity of CNV profiles are seen from both CRC cell lines and CRC primary tumor samples with highlight on chromosome 13 copy number gain. Supplementary Figure S2: The RNA expression levels comparison between the sensitive and resistant groups in all cell lines, KRAS mutants, KRAS/BRAF-WT/WT subpopulations for IR-B, IGF1, IGF2 and IRS1. Supplementary Figure S3: Differential expression patterns of IRS2, IGF-1R, and activation of MAPK between CRC cell lines with KRAS G13D mutation and other KRAS mutations. Supplementary Figure S4: Cell lines with IRS2 CNG or sensitive to BMS-754807 had lower basal level MAPK activation. Supplementary Figure S5: IGF-1R/IR pathway signaling in LS513 and SW-403 CRC cell lines.



Insulin-like growth factor receptor 1 (IGF-1R)–targeting therapies are currently at an important crossroad given the low clinical response rates seen in unselected patients. Predictive biomarkers for patient selection are critical for improving clinical benefit. Coupling in vitro sensitivity testing of BMS-754807, a dual IGF-1R/IR inhibitor, with genomic interrogations in 60 human colorectal cancer cell lines, we identified biomarkers correlated with response to BMS-754807. The results showed that cell lines with BRAFV600E or KRASG13D mutation were resistant, whereas cell lines with wild-type of both KRAS and BRAF were particularly sensitive to BMS-754807 if they have either higher RNA expression levels of IR-A or lower levels of IGFBP6. In addition, the cell lines with KRAS mutations, those with either insulin receptor substrate 2 (IRS2) copy number gain (CNG) or higher IGF-1R expression levels, were more sensitive to the drug. Furthermore, cell lines with IRS2 CNG had higher levels of ligand-stimulated activation of IGF-1R and AKT, suggesting that these cell lines with IGF-IR signaling pathways more actively coupled to AKT signaling are more responsive to IGF-1R/IR inhibition. IRS2 siRNA knockdown reduced IRS2 protein expression levels and decreased sensitivity to BMS-754807, providing evidence for the functional involvement of IRS2 in mediating the drug response. The prevalence of IRS2 CNG in colorectal cancer tumors as measured by qPCR-CNV is approximately 35%. In summary, we identified IRS2 CNG, IGF-1R, IR-A, and IGFBP6 RNA expression levels, and KRAS and BRAF mutational status as candidate predictive biomarkers for response to BMS-754807. This work proposed clinical development opportunities for BMS-754807 in colorectal cancer with patient selection to improve clinical benefit. Mol Cancer Ther; 14(2); 620–30. ©2014 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager